Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL4I1 | Q96RQ9 | 5/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30948081 | 0.89 | IL4I1 (0.50) | IL4I1EPHX2MAPTSMN1; SMN2CA12 | |
| SCHEMBL30948059 | 0.79 | IL4I1 (0.76) | IL4I1EPHX2MAPTSMN1; SMN2KCNH2 | |
| SCHEMBL30948229 | 0.79 | IL4I1 (0.79) | IL4I1EPHX2MAPTSMN1; SMN2KCNH2 | |
| SCHEMBL30948223 | 0.78 | IL4I1 (0.52) | IL4I1EPHX2MAPTSMN1; SMN2HSD17B13 | |
| SCHEMBL30947992 | 0.76 | IL4I1 (0.59) | IL4I1MAPTSMN1; SMN2CA12CA9 | |
| SCHEMBL30948008 | 0.73 | IL4I1 (0.46) | IL4I1SMN1; SMN2HSD17B13HRH3DRD3 | |
| SCHEMBL30948375 | 0.72 | IL4I1 (0.64) | IL4I1MAPTSMN1; SMN2CA12CA9 | |
| SCHEMBL30948248 | 0.71 | IL4I1 (0.48) | IL4I1MAPTSMN1; SMN2CA12CA9 | |
| SCHEMBL30948169 | 0.67 | IL4I1 (0.48) | IL4I1HSD17B13HRH3 | |
| SCHEMBL30947922 | 0.67 | IL4I1 (0.96) | IL4I1MAPTSMN1; SMN2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | IL4I1 1/4885EPHX2 3776/4885MAPT 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.